| 08.27.24 | ADC biotech Duality plans IPO; Navigator nets $100M for newly acquired autoimmune assets

Laden...

2 maanden geleden

Html
Tekst

Publisher’s Note: Join Fierce Biotech Editors and industry leaders at the Fierce Biotech Summit to network and gain exclusive insights. Don’t miss out — register now!

IQVIA Patient Suite: Implement the Right Technology at the Right Time for Your Trial

Join IQVIA Patient Suite experts Kevin Landells and Anthony Mikulaschek in this webinar as they explore the flexibility in choosing the right approach for integrating patient technology into your next trial. Whether you opt for an integrated solution or individual technology products, this webinar will guide you through the decision-making process to ensure you’re executing a patient technology strategy that fits your needs.

Today’s Big News

Aug 27, 2024

Duality plans Hong Kong IPO to fund trials of BioNTech-partnered ADCs and beyond

Navigator charts course for newly acquired autoimmune pipeline with $100M series A

Vaderis scores win against rare blood vessel disorder as trial shows its drug reduces nosebleeds

Molecular Partners rethinks tetra-specific dosing after seeing 'suboptimal exposure' in cancer trial

After J&J-partnered epilepsy drug flop, Addex gets good news: Indivior has picked up its addiction asset

Federal health agency awards University of Illinois over $50M to improve tumor treatment, R&D

YolTech sells China rights to cholesterol gene editing therapy to Salubris for $29M

Fierce L ife Sciences Innovation Awards

Shape the Future of Life Sciences

Entries for the Fierce Life Sciences Innovation Awards are coming to a close September 5th, 2024. Submit your entry & lead the charge in life sciences innovation. Enter now!

Featured

Duality plans Hong Kong IPO to fund trials of BioNTech-partnered ADCs and beyond

By Nick Paul Taylor

China’s Duality Biotherapeutics has filed paperwork for a Hong Kong IPO, seeking an undisclosed sum to power a broad pipeline of antibody-drug conjugates toward approval. The filing extends the recent flurry of IPO activity beyond the U.S. and into Asia.

Navigator charts course for newly acquired autoimmune pipeline with $100M series A

By James Waldron

Navigator Medicines has equipped itself with $100 million in series A funds as the young biotech charts a course for its newly acquired autoimmune drugs.

Vaderis scores win against rare blood vessel disorder as trial shows its drug reduces nosebleeds

By James Waldron

Vaderis Therapeutics’ goal to develop the first drug aimed specifically at a certain rare blood vessel disorder came one step closer today with the news that the therapy is safe and reduced nosebleeds.

The Evolving Alzheimer’s Disease Landscape

Specialty Immunoassays from RBM to Support your Clinical Trials

Luminex MAP profiles
Ultrasensitive Simoa
Olink Target 48 Cytokine

Molecular Partners rethinks tetra-specific dosing after seeing 'suboptimal exposure' in cancer trial

By Nick Paul Taylor

Molecular Partners has identified “suboptimal exposure” to its tetra-specific T-cell engager as the potential cause of the limited response rate in its early-phase trial, prompting the Swiss biotech to change the protocol to try to dial up the impact of the compound.

The Crucial Role of HEK293 DNA Quantification in Biotherapeutics

After J&J-partnered epilepsy drug flop, Addex gets good news: Indivior has picked up its addiction asset

By Gabrielle Masson

Indivior is picking up a small molecule allosteric modulator designed to treat substance use disorder from Addex Therapeutics, providing the latter the chance to make up to $300 million in biobucks, plus royalties.

Federal health agency awards University of Illinois over $50M to improve tumor treatment, R&D

By Darren Incorvaia

The department has granted engineering groups at the University of Illinois Urbana-Champaign two awards totaling about $54 million to develop new techniques for both studying and surgically removing tumors.

YolTech sells China rights to cholesterol gene editing therapy to Salubris for $29M

By James Waldron

Four months after Chinese gene editing company YolTech Therapeutics took its cholesterol disease-focused candidate into the clinic, Salubris Pharmaceuticals has secured the local rights to the drug for 205 million Chinese yuan ($28.7 million).

AstraZeneca plans $135M expansion of Swedish biologics production site

By Joseph Keenan

British pharma giant AstraZeneca plans to spend $135 million to expand the manufacturing operations footprint of its site in Södertälje, Sweden, by 50%.

Sanofi halts flu vaccine distribution in China over fear of declining potency

By Angus Liu

Sanofi has temporarily stopped distributing and selling its flu shots in China out of concerns of waning potency.

Siemens Healthineers to acquire Novartis' European radiodiagnostic manufacturing network

By Conor Hale

Siemens Healthineers aims to grow its PET imaging business by picking up the radiodiagnostic manufacturing and distribution network of Novartis’ Advanced Accelerator Applications division.

Fierce podcasts

Don’t miss an episode

What Chevron’s overturn means for biopharma

This week on "The Top Line," we look at the potential effects of the Chevron overturn on the biopharma industry.

How incentives engage and keep patients healthy

The TROP2 race for supremacy


A message from The American Society for Bone and Mineral Research

Resources

Whitepaper

Epilepsy Clinical Trials

Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner.

Launching a Product in Europe: Understanding Supply Chain Cost Drivers

This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs.